Protagonist Therapeutics Investor Presentation — January 2022

Document content

Dinesh V. Patel, PhD | President & CEO

January 2022Forward- looking Statements

2This presentation and the accompanying oral presentation contain forward -looking statements made pursuant to the safe harbor provisions of the

Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including

statements regarding our future results of operations and financial position, business strategy, product candidates, capital resources, potential markets

for our product candidates, enrollment in our clinical trials, any potential impact on our business related to COVID-19, our pot ential receipt of milestone

payments and royalties under our Collaboration Agreement with Janssen Biotech, Inc., are forward-looking statements. In some ca ses, you can identify

forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially”

“predict,” “should,” “will” or the negative of these terms or other similar expressions.

The forward -looking statements made in this presentation involve known and unknown risks, uncertainties and other important fact ors that may cause

our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by

the forward -looking statements. These forward -looking statements are subject to risks and uncertainties, including those discussed in Protagonist’s

filings with the Securities and Exchange Commission, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition

and Results of Operations” sections of most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents

incorporated by reference therein. Because forward -looking statements are inherently subject to risks and uncertainties, some of which cannot be

predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future

events. The events and circumstances reflected in our forward -looking statements may not be achieved or occur and actual results could differ materially

from those projected in the forward -looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward -

looking statements contained herein, whether as a result of any new information, future events, changed circumstances or othe rwise.

This presentation concerns products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug